RT Journal Article
SR Electronic
T1 Aging and COVID-19 mortality: A demographic perspective
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.15.20213454
DO 10.1101/2020.10.15.20213454
A1 Sasson, Isaac
YR 2020
UL http://medrxiv.org/content/early/2020/12/08/2020.10.15.20213454.abstract
AB Demographers have emphasized the importance of age in explaining the spread and impact on mortality of COVID-19. However, the relationship between COVID-19 with age should be contextualized in relation to other causes of death. This study set out to compare the age pattern of COVID-19 mortality with other major causes of death and across countries, and to use these regularities to impute age-specific death counts in countries with partial data. Using US vital Statistics, the COVID-19 mortality doubling time in a Gompertz context was compared with 65 major causes of death. COVID-19 fatality and mortality doubling times were similarly compared within and between 27 countries, using harmonized demographic databases of confirmed COVID-19 cases and deaths. Several findings are supported by the empirical evidence. First, COVID-19 mortality increases exponentially with age at a Gompertz rate near the median of aging-related causes of death, as well as pneumonia and influenza. Second, COVID-19 mortality levels are 2.8 to 8.2 times higher than pneumonia and influenza across the adult age range. Third, the relationship between both COVID-19 fatality and mortality with age varies considerably across countries. Fourth, COVID-19 deaths by age are imputed for Israel as a case in point. In conclusion, the increase in COVID-19 mortality with age resembles the population rate of aging. Country differences in the age pattern of COVID-19 fatality and mortality may point to differences in underlying population health, standards of clinical care, and data quality. This study underscores the need to contextualize the age pattern of COVID-19 mortality in relation to other causes of death.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The analysis is based on aggregate, publicly available data and does not require IRB approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are publicly available. https://wonder.cdc.gov/ https://osf.io/mpwjq/ https://dc-covid.site.ined.fr/en/